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Abstract: 
Background:  Elevated levels of CD23, a natural regulator of IgE production, have been shown 
to decrease the signs of lung inflammation in mice. The aim of this study was to study the 
involvement of ADAM10, the primary CD23 sheddase, in experimental asthma. 
Methods:  ADAM10 was blocked either by using mice with a B-cell-specific deletion of the 
protease or pharmacologically by intranasal administration of selective ADAM10 inhibitors. 
Airway hypersensitivity (AHR) and bronchoaveolar lavage fluid (BALF) eosinophilia and select 
BALF cytokine/chemokine levels were then determined. 
Results:  Using an IgE and mast cell–dependent mouse model, B-cell-specific 
ADAM10−/− mice (C57B/6 background) exhibited decreased eosinophilia and AHR when 
compared with littermate (LM) controls. Treatment of C57B/6 mice with selective inhibitors of 
ADAM10 resulted in an even further decrease in BALF eosinophilia, as compared with the 
ADAM10−/− animals. Even in the Th2 selective strain, Balb/c, BALF eosinophilia was reduced 
from 60% to 23% respectively. In contrast, when an IgE/mast cell–independent model of lung 
inflammation was used, the B-cell ADAM10−/− animals and ADAM10 inhibitor treated animals 
had lung inflammation levels that were similar to the controls. 
Conclusions:  These results thus show that ADAM10 is important in the progression of IgE-
dependent lung inflammation. The use of the inhibitor further suggested that ADAM10 was 
important for maintaining Th2 levels in the lung. These results thus suggest that decreasing 
ADAM10 activity could be beneficial in controlling asthma and possibly other IgE-dependent 
diseases. 
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Article: 
The contribution of IgE to allergy was first established in the late 1960s (1), and with the 
development of anti-IgE therapy, its role in asthma has become better appreciated. In 
experimental asthma models in mice, the therapy leads to decreases in lung eosinophil 
infiltration, reduced airway hypersensitivity (AHR), and decreased IL-5 and IL-13 production (2), 
which effects are also seen in human patients (3). Although clearly beneficial, its cost-
effectiveness in severe asthmatics has been questioned (4). In addition, anti-IgE therapy is only 
approved for those whose IgE levels fall in the 30 and 700 IU/ml range (5). Thus, additional 
therapies, especially for patients with IgE levels in excess of this range are needed. 
CD23, the low affinity-receptor of IgE, is a type II integral transmembrane protein. It is 
predominantly expressed as a trimer at the cell surface (6) and it is in this oligomerized state that 
CD23 bound to IgE can decrease the synthesis of IgE (7). CD23 is a member of the C-type lectin 
family, making it unique among Fc receptors. IgE is bound by the lectin head of CD23 and the 
trimer has an effective affinity for IgE in the nM range. In addition to being a membrane-bound 
protein, CD23 after cleavage, is also found as a soluble factor (sCD23). In humans, CD23 has 
been shown to have the opposite role of membrane CD23, as it increases B-cell proliferation and 
IgE synthesis (8). 
When administered in conjunction with antigen, agonist antibodies specific for the IgE binding 
site of CD23 cause decreased levels of IgE while having no effects on other isotypes (9). Anti-
CD23 also decreased signs of experimental asthma in both IgE-dependent and IgE-independent 
mouse models (10). One study (10) additionally examined CD23 transgenics with respect to 
experimental asthma induction and found decreased eosinophils in the bronchoaveolar lavage 
fluid (BALF) as well as reduced AHR (by penh); however, no mechanism was presented. 
Finally, when anti-CD23 therapy was used in a clinical trial, there was a 40% drop in free serum 
IgE (11). While not sufficient for clinical efficacy, this trial did show that CD23 is a useful target 
to decrease IgE levels in humans. 
The identification of A Disintegrin and Metalloproteinase 10 (ADAM10) as the primary CD23 
sheddase (12) suggests an alternative method to promote the CD23 regulatory activity of IgE, 
namely by modulating B-cell ADAM10 levels and/or activity. The ADAM10-mediated cleavage 
of CD23 primarily takes place after CD23 is sorted into exosomes in an ADAM10-dependent 
manner (13). While global ADAM10−/− mice die at embryonic day 9.5, ADAM10 B cell 
conditional knock outs (called ADAM10−/− from this point) have a large increase in surface 
CD23 and a corresponding decrease in sCD23 (14). Additionally, we have recently shown that the 
inhibition of ADAM10 in human B cell in vitro cultures decreases the synthesis of IgE (15). In 
this study, we show that when surface levels of CD23 are increased, the features of IgE-
dependent experimental asthma are reduced. We show that CD23Tg mice and ADAM10 B-cell-
specific knockouts, which both have high levels of surface CD23, are less susceptible to IgE-
dependent asthma. Furthermore, we show that treatment of mice intranasally with ADAM10 
inhibitors show substantially reduced responses to ovalbumin (OVA). The mechanism is 
potentially because of a reduction in IgE and/or in the Th2 response. 
Material and methods 
Reagents 
Chicken OVA and Imject alum adjuvant were purchased from Sigma (St. Louis, MO, USA) and 
Pierce (Rockford, IL, USA), respectively. Cytokines were measured using multiplex kits from 
Biorad (Hercules, CA, USA) according to the manufacturer’s instructions. The ADAM10 
hydroxamate inhibitors, INC008765 and INC009588 (16), were synthesized by the Incyte 
Corporation. These inhibitors are very selective for ADAM10 as shown by both cell free as well 
as cell-based assays requiring at least 5 fold higher concentrations to inhibit MMP12 and at least 
20 fold to inhibit any other enzymes including ADAM17 (16). 
Mice 
CD23 transgenics were described previously (17) and have been backcrossed 12 generations onto 
a Balb/c background. Littermates that were negative for the transgene were used as controls. B-
cell-selective ADAM10−/− mice were also described previously (14) and are on a C57B/6 
background. Mice negative for the cre gene were used as littermate (LM) controls. Female 
C57BL/6J and Balb/c mice were purchased from Jackson laboratory (Bar Harbor, ME, USA) and 
were used in the inhibitor studies. Female mice aged 8–12 weeks were used in the experiments. 
All mouse protocols were approved by the VCU Institutional Animal Care and Use Committee. 
Asthma models 
Two asthma models were used and are shown in Fig. 1. Model A was developed by Williams 
and Galli (18) and was shown to be mast cell as well as IgE dependent. For Figs 2 and 3 this 
model was slightly modified mice were only injected four times with 50 μg OVA, then they were 
challenged starting on day 22. Galli has shown this modified model is also IgE/mast cell 
dependent (private communication). Model B was developed here at VCU and was shown to be 
independent of IgE and mast cells through the use of IgE−/− (19) and mast cell–deficient mice 
(W/Wsh); in both cases, the eosinophil levels in the BALF and lung tissue were similar to wild-
type mice (data not shown). 
 
Figure 1.  Models of asthma used. (A) Mast cell/IgE-dependent model. This model (18) was used 
normally in Figs 4 and 5C,D or with modification as explained in Materials and methods in Figs 
2A,C and 3. Called Model A in text. (B) Mast cell/IgE-independent model. Called Model B in 
text. 
 
Figure 2.  Overexpression of CD23 in CD23Tg can control eosinophilia in an IgE-dependent 
model but not an IgE-independent model. (A) Asthma was induced in Balb/c littermates (LM) 
and CD23Tg using model A. Bronchoaveolar lavage fluid (BALF) were collected and the 
percentages of cells were determined as explained in the Material and methods by counting at 
least 100 cells. Shown is the average of four mice. (B) Asthma was induced in Balb/c LM and 
CD23Tg using model B. The percentages of cells were determined as in A. Shown in the average 
of at least four mice per group. (C) The cytokines in the BALF of the mice used in A were 
determined using multiplex kits according to the manufactures’ instructions. *Pvalue < 0.05 and 
**P value < 0.001. 
 
Figure 3.  Conditional removal of ADAM10 decreases the severity of disease in a IgE/mast 
cell–dependent model. (A) Mice were sensitized and challenged using model A (mice are on a 
C57B/6 background). On day 29, lung function was assessed by measuring total lung resistance 
as explained in the Material and methods; shown is the average of at least 4 mice per treated 
group. Significance is between ADAM10−/− and littermate. (B) Rn (Newton Resistance), Tissue 
Dampening and Elastance were determined at baseline (PBS) and after the addition of 50 mg/ml 
of methacholine, with the average of the three maximum points at each dose being used for each 
mouse. Shown is the average of at least 4 mice per group. (C) Cells from the bronchoaveolar 
lavage fluid (BALF) were counted and stained as explained in the Material and methods. 
Percentages of cells were then determined in the BALF by counting of at least one hundred cells, 
and numbers presented are the average of at least four mice. (D) The levels of OVA-specific IgE 
in the serum were determined by ELISA, shown is the average of at least five animals. (E) 
Cytokine levels in the BALF was determined by multiplex analysis, shown is the average of at 
least four animals (same key as in C). *P value <0.05, **P value < 0.01 and ***P value < 0.001. 
FlexiVent 
In some experiments, 18 h after the final OVA challenge, airway resistance was measured using 
the Flexivent system (Scireq, Montreal, QC, Canada) (19). Mice were anesthetized by 
intraperitoneal (IP) injection of 206.7 mg/kg of ketamine and 41.7 mg/kg of xylazine. Following 
cannulation and paralyzation, mice were ventilated and measurements of baseline lung function 
were taken, mice were exposed to aerosols containing increased doses (10, 25, 50 mg/ml for 
C57B/6 or 2.5, 5, 10, 25 for BALB/c) of Acetyl-β-methylcholine chloride (Methacholine) 
(Sigma). Newtonian resistance (Rn), tissue damping, and tissue elastance were all measured at 
baseline (PBS) and 50 mg/ml of methacholine using the Flexivent software version 5.3. 
BALF/lung collection 
Following the Flexivent analysis, BALF was collected by lavaging the lungs with 1 ml PBS. The 
BALF was centrifuged and supernatant fluids were saved for further analysis. Pelleted cells were 
resuspended in 100 μl PBS, counted, cytospun onto slides, and stained with Diff-Quik (Siemens 
Healthcare Diagnostics, Deerfield, IL, USA). Percentages were determined by counting of at 
least 100 leukocyte cells per cytospin. Additionally, lung and heart tissue were fixed in 10% 
formalin (Fisher) and embedded in paraffin by the VCU pathology core. Five micrometer 
sections were cut onto microscope slides and stained with hemotoxin and eosin (H&E). A Nikon 
eclipse with a SPOT Flex Shifting Pixel Color Mosaic (Diagnostic Instrumental Inc., Sterling 
Heights, MI, USA) camera was used to take pictures of the sections. 
ELISAs 
Total mouse IgE was measured as previously described (20). For OVA-specific IgE, R1E4 (rat 
anti-mouse IgE) was used as the capture antibody and OVA-DNP-Biotin in combination with 
Streptavidin-alkaline phosphatase (AP) was used for detection. Mouse IgE anti-DNP was used as 
a standard. For OVA-specific IgG1, OVA was used to capture the antibody. Samples and 
standard (serum from a mouse hyper immunized with OVA was used as an internal control) were 
detected with an AP-goat anti mouse IgG1. The liver enzymes aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT) were measured as previously described (21). 
Real time PCR 
Total RNA was extracted from disrupted lung tissue and purified as explained previously (14). For 
analysis, the following previously published primers were used: GATA3 (22), T bet (22), IL-25 
(23), and IL-33 (23). 
Statistics 
All statistics were done using the student two-tailed t-test, with Bonferroni correction when 
multiple comparisons were being made. All bars represent standard error. 
Results 
ADAM10−/− and CD23Tg mice have decreased signs of allergic lung inflammation in an 
IgE-dependent model 
To test the importance of CD23 and ADAM10 in asthma induction, we used the murine models 
of allergic lung inflammation shown in Fig. 1. In agreement with Haczku et al.(10), we found that 
CD23Tg mice (Balb/c background), which have suppressed IgE (17) and have high expression of 
CD23 on lymphocytes, exhibited decreased eosinophilia (Fig. 2A) when tested in an IgE-
dependent asthma model (model A). We also observed decreased levels of the chemokine IL-5 
(Fig. 2C), which may explain the decreased eosinophilia seen. In contrast to the IgE-dependent 
model (model A), no differences in BALF eosinophilia was seen (Fig. 2B) when model B was 
used. This indicates that the decrease in asthma severity observed in the CD23Tg occurs because 
of decreased IgE in these animals. Given that ADAM10 is the CD23 sheddase and that mice 
which lack B-cell ADAM10 have greatly increased CD23 expression (14), we next tested 
whether these mice would have reduced inflammation with model A. Lung AHR in 
ADAM10−/− mice (C57B/6 background), as determined by total lung resistance (RL) (Fig. 3A) 
and forced oscillation technique (Fig. 3B) was significantly lower than in the LM sensitized 
mice.Fig. 3C shows that the ADAM10−/− mice also had significantly reduced eosinophilia in the 
BALF. Total BALF cell numbers (data not shown) and percentages of other cell types in the 
ADAM10−/− mice closely resembled the unsensitized animals. ADAM10−/− mice also had 
reduced serum antigen-specific IgE levels (Fig. 3D). In addition, significant decreases in both 
Th1 and Th2 cytokines were observed (Fig. 3E). In contrast, when asthma was induced with 
model B, the ADAM10−/− (data not shown) like the CD23Tg (Fig. 2B) was not significantly 
different from the LM sensitized animals with respect to AHR or BALF eosinophilia (data not 
shown). Additionally, the Th1 cytokines IL-12 and MIP1-α were still significantly decreased in 
the IgE-independent model, when comparing the OVA-sensitized ADAM10−/− mice with LM 
controls (data not shown). Overall, these data show that increasing CD23 by inhibiting ADAM10 
on B cells has the potential for strongly inhibiting the IgE-dependent lung inflammatory 
response, but not the IgE-independent lung inflammatory response by reducing IgE levels. 
ADAM10 inhibition blocks the induction of experimental asthma 
Given the aforesaid finding that mice lacking B-cell ADAM10 have minimal pathology in IgE-
dependent lung inflammation, we sought to determine whether inhibiting ADAM10 activity in 
WT mice would have the same affect. Experiments were conducted with two hydroxamate 
inhibitors of ADAM10 (both were found to act similar, thus the data from both were combined). 
They were dissolved in DMSO and administered intranasally during the induction of the asthma 
model. The inhibitors were administered intranasally at a concentration of 1 mg/kg (16), a dose 
where ADAM10 should selectively be inhibited, in DMSO/PBS every 3 days throughout the 
experiment. As a control, the ADAM10 inhibitors were also administered to unsensitized mice 
and found to have no effect (Fig. 4B,C). Using the IgE-dependent model (model A), we found 
that the inhibitors significantly decreased the signs of allergic airway inflammation, while having 
no toxic effects as measured by weight loss as well as the levels of liver enzymes (ALT, AST) in 
the serum (Table 1). The carrier (5% DMSO in PBS) was well tolerated; responses of the LM 
controls in Fig. 3C were similar to Fig. 4C. Thus, any reduction in asthma severity was because 
of inhibition of ADAM10 activity. We also found that similar to the ADAM10−/− (Fig. 3), AHR 
as measured by forced oscillation technique (Fig. 4B), as well as RL (Fig. 4A) was decreased by 
the administration of the ADAM10 inhibitor. The eosinophilia in the BALF was also found to be 
significantly reduced (Fig. 4C); this decrease was even more drastic than in the ADAM10−/−, 
from approximately 50% to 20% in the ADAM10−/− (Fig. 3C) and from approximately 50% to 
5% (Fig. 4C) in WT mice treated with the inhibitor. Thus, this shows that ADAM10 expression 
by other cells, in addition to the B cell, is important in the progression of experimental asthma. 
The inhibitors are also possible blocking ADAM10 activity on epithelial cells as they have been 
shown to control the allergic response (reviewed in 24) and have high expression of ADAM10 
(25). Of note although the percentage of macrophages was increased, there were actually similar 
amounts of macrophages in the BALF (data not shown) after inhibitor treatment. To determine 
whether this effect was through an inhibition of IgE synthesis, as it was with the ADAM10−/−, we 
measured the levels of total IgE in the serum (Fig. 4D) but found it was unchanged from the 
DMSO treated mice. However, local production was decreased, as total IgE in the BALF was 
significantly decreased (Fig. 4E). Hydroxamate inhibitors are known to have a short half-life in 
serum (26); however, as clearly shown by our data when administered intranasally the inhibitory 
activity is sufficient for at least a 3-day period. The effects on IgE suggest local activity, 
however, blocking only the local production of IgE is advantageous as it has been shown that 
local but not systemic, production of IgE (27) is important for disease progression. 
 
Figure 4.  ADAM10 inhibitor blocks the induction of an IgE/mast cell–dependent model 
potentially through blocking the Th2 response. Asthma was induced using the IgE-dependent 
model (Model A). 1 mg/kg in a 20:1 mixture of PBS/DMSO of an ADAM10 inhibitor (called 
A10 Inh in figure) was injected intranasally every 3 days throughout the experiment in wild-type 
C57B/6. The control mice (wild-type C57B/6) received just the PBS/DMSO mixture. (A) On day 
47, airway hypersensitivity was measured using total lung resistance (significance is between 
ADAM10 inhibitor and DMSO treated) and (B) forced oscillation measurements as explained 
in Fig. 3B. Data represent the average of data from at least four sensitized mice and two 
unsensitized mice. (C) Percentages of bronchoaveolar lavage fluid (BALF) cells were 
determined as in Fig. 2A. Shown is the average of at least three animals (same key as B). (D) 
Total IgE in the serum as determined by ELISA, average of at least four animals. (E) Total IgE 
in the BALF as determined by ELISA, average of at least three animals. (F) qRT-PCR of total 
lung RNA was performed using the primers listed in Material and methods. Shown is the average 
of at least five animals. The unsensitized groups were combined, as no difference were seen 
between them. (G) BALF cytokine levels as determined by multiplex ELISA. Shown is the 
average of at least five animals per group. Again unsensitized groups were combined. (same key 
as F). Number above comparison line equals P value, *P value < 0.05 and **Pvalue < 0.01. 
Table 1.  Liver enzyme analysis indicates lack of toxicity for ADAM10 inhibitors 
Parameter DMSO – ovalbumin (OVA) 
sensitized 
ADAM10 inh – OVA 
sensitized 
Weight (time of sacrifice) 20.49 ± 0.50 20.43 ± 0.28 
Aspartate aminotransferase 
(AST) 
13.666 ± 6.81 15.558 ± 6.87 
Alanine aminotransferase 
(ALT) 
2.59 ± 0.93 3.64 ± 0.67 
Just prior to measurement of airway hypersensitivity, the mice were weighed. Shown is the average of at 
least 8 mice per group. The serum isolated after the killing of three mice of similar treatment were pooled 
together and then AST and ALT levels were measured in the serum as explained in the Material and 
methods. Shown is the average of at least two different pools. 
To test whether ADAM10 inhibitors had further effects beyond that of inhibiting IgE, we 
isolated total lung mRNA from treated and control mice, and using qRT-PCR, we measured the 
level of several components known to be important in asthma progression, including the Th2 
response. In the ADAM10−/− mice, we found that the decrease in serum OVA-specific IgE 
correlated with a decrease in Th2 cytokines (Fig. 3E). To test what effect administration of the 
inhibitor was having on T-cell responses, mRNA levels of the dominate T-cell transcription 
factors were measured by qRT-PCR. Analysis demonstrated that GATA3 message levels were 
significantly decreased, while Tbet was not (Fig. 4F). Recently two cytokines, IL-25 and 33 
(reviewed in 28), have been implicated in the induction of a Th2 response. While minimal IL-25 
levels were detected, message for IL-33 was significantly decreased in mice treated with the 
ADAM10 inhibitor. These results show that ADAM10 is also important in the initiation of the 
Th2 response in the lung. Interestingly, when cytokines were analyzed in the BALF, IL-13 levels 
were not decreased (Fig. 4G) when given the inhibitor, in spite of the known association of IL-13 
and AHR (29). Alternative cell sources, not affected by ADAM10 inhibition, of IL-13 
production (30) could potentially explain this finding. It is interesting to speculate that blockade 
of ADAM10 decreases IL-13 ability (29) to act on epithelial cells in the lung. The decreased 
eosinophilia (Fig. 4C) observed after ADAM10 inhibition can be explained by the strong 
inhibition of IL-5, the primary chemotactic factor in the recruitment of eosinophils, as well as by 
significant decreases in eotaxin and KC which are also involved in eosinophil recruitment 
(Fig. 4G). Finally, IL-9 was also found to be decreased by the addition of the ADAM10 
inhibitor. IL-9 is produced both by Th2 cells and by the new subclass of T helper cells, Th9, and 
is known to enhance airway inflammation (31). Overall, the multiple changes help explain how 
the inhibition of ADAM10 suppresses IgE-dependent lung inflammation. 
In order to confirm our findings in the BALF lung sections from both the ADAM10−/− and 
inhibitor treated and their respective controls were stained with H&E. As is seen by the 
representative pictures in Fig. 5A,C that when ADAM10 was blocked either genetically or with 
an inhibitor, there was a decrease in inflammation compared with their controls (Fig. 5B,D), 
including the infiltration of eosinophils. These results thus show that ADAM10 is important not 
only in the recruitment to the BALF of eosinophils but also to the lung tissue. 
 
Figure 5.  ADAM10 inhibition also blocks the inflammatory response in the lung tissue. The 
lungs from mice where asthma had been induced using Model A, were fixed and sectioned as 
explained in the Material and methods. The sections were then de-paraffinized and stained with 
H&E. Larger photomicrographs are 10× with select inserts from areas showing obvious 
inflammation at 100x. (A) Photomicrographs using lungs from ADAM10−/−mice or (B) their 
littermate controls. (C) Photomicrographs using lungs from C57B/6 that received INC008765 
throughout the induction of asthma or (D) DMSO control lungs. Photographs shown are 
representative from experiments using 4 mice per group. 
When the ADAM10 inhibitor administration was repeated in BALB/c mice using model A, 
similar results were seen except the eosinophilia decrease in the BALF was not as drastic (60–
23% in the Balb/c compared to 50–5% in the C57B/6 after inhibitor treatment). Finally, when the 
ADAM10 inhibitor was administered every 3 days during the induction of model B (IgE 
independent), no effect was seen. Overall, these results show that regardless of the mouse 
background, the administration of an ADAM10 inhibitor is able to block the induction of 
experimental asthma. 
Discussion 
Although it has previously been shown that if the cleavage of CD23 is blocked with a stabilizing 
antibody or if CD23 is overexpressed that the signs of lung inflammation were decreased (10), it 
was not known what role ADAM10 played in this or how CD23 was able to control lung 
inflammation. Herein, we showed that overexpression of CD23 or blocking ADAM10 decreases 
the Th2 response as well as the other signs of lung inflammation, including eosinophilia, AHR, 
and IgE production. 
The mechanism of the reduced signs of experimental asthma after ADAM10 inhibition is 
currently under investigation. Based on the findings reported, we propose two possibilities. First, 
as we found that administration of the inhibitor blocked IgE production (Fig. 3E), this decrease 
in IgE would be reflected in decreased mediators released from mast cells after antigen 
challenge, thus resulting in decreased signs of experimental asthma, including AHR. One of the 
reasons for decreased IgE production is reduced cleavage of CD23, as we have previously shown 
that inhibitors of ADAM10 (15) and loss of ADAM10 (14) reduce CD23 cleavage both in 
vitro and in vivo respectively. Additionally, using a hu-PBL model in SCID mice, the inhibition 
of CD23 cleavage was previously shown to correlate with decreased IgE synthesis (32). Second, 
the stimulatory activity of IgE complexes that bind with CD23 and enhance antigen presentation 
has been well documented by the Heyman laboratory (reviewed in 33). In a recent study, we 
showed that ADAM10 is not only the sheddase of CD23, but also sorts CD23 into exosomes (13). 
Once released from the cell, the CD23 containing exosomes could bind IgE complexes and cause 
increased antigen presentation and T-cell responses. The ADAM10 B-cell conditional knockouts 
do not have these CD23 containing exosomes (13), and the lack of these CD23 containing 
exosomes could possibly explain part of the inhibition of the Th1, as well as the Th2, responses. 
Such exosomes, containing bound IgE complexes, would be anticipated to enhance dendritic cell 
activation of T cells. 
Overall, the combination of using B-cell ADAM10 knockouts, as well as hydroxamate inhibitors 
of ADAM10, clearly indicates an important role for ADAM10, and CD23, in Th2-induced 
asthmatic disease, and suggests that hydroxamate inhibitors of ADAM10, directly administered 
to the airway, may have utility to modulate this disease. 
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